Aduro discontinues development of CRS-207
Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and ovarian cancer. Aduro said it will now focus on its transmembrane protein 173 (STING; TMEM173) agonist program, B-select mAbs and personalized live-attenuated double-deleted Listeria monocytogenes (LADD) immunotherapy utilizing tumor neoantigens.
CRS-207 is a LADD that expresses human mesothelin. The candidate was in a Phase I/II trial to treat ovarian cancer; a Phase II trial in combination with Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) to treat malignant pleural mesothelioma; and a Phase II trial in combination with Keytruda to treat gastric cancer. The ovarian cancer trial evaluated CRS-207 alone, in combination with epacadostat (INCB24360) from Incyte Corp. (NASDAQ:INCY), in combination with Keytruda, or in combination with both epacadostat and Keytruda...